
Valeant stock has risen 46% so far this month, but we still can't find a good reason to buy.
The company is still struggling from its 2015 price hike scandal, and that should not be ignored.
By Ashley Moore, Associate Editor, Money Morning -
Valeant stock has risen 46% so far this month, but we still can't find a good reason to buy.
The company is still struggling from its 2015 price hike scandal, and that should not be ignored.
By Ashley Moore, Associate Editor, Money Morning -
Valeant stock has risen 46% so far this month, but we still can't find a good reason to buy.
The company is still struggling from its 2015 price hike scandal, and that should not be ignored.
By Diane Alter, Contributing Writer, Money Morning -
Valeant stock is down today after the company reported dismal earnings.
Shares were down more than 20% in morning trading following disappointing Q3 2016 results and gloomy guidance.
Here are all the grim details...
By Diane Alter, Contributing Writer, Money Morning -
Major Valeant Pharmaceuticals news out late yesterday had the VRX stock price soaring more than 34%.
After investors had time to digest the news and that a deal is not certain, shares fell.
Here's why we remain bearish on Valeant moving forward...
By Diane Alter, Contributing Writer, Money Morning -
Valeant stock is down again, and it's year-to-date losses have now topped 82%.
The Valeant stock price sank Monday amid reports of a new criminal investigation into the company's former leaders.
By Diane Alter, Contributing Writer, Money Morning -
The Valeant stock price surged more than 25% this week after the firm released Q2 earnings.
But shares of VRX are down nearly 10% again today, and we think they're heading much lower.
In fact, we think the company will go bankrupt. Here's why...
By Diane Alter, Contributing Writer, Money Morning -
The Valeant stock price is up 2% today, one day after a 13% jump on Wednesday. The jump occurred after Walgreens Boots Alliance Inc. (Nasdaq: WBA) said it is pleased with its Valeant relationship.
We remain bearish on the Valeant stock price and we're not buying into the rally.
By Diane Alter, Contributing Writer, Money Morning -
Valeant Pharmaceuticals stock just received another kick in the teeth this morning.
Shares of VRX are down more than 22% after the company reported a dismal Q1 loss.
But we see the stock price going even lower this year...
By Diane Alter, Contributing Writer, Money Morning -
The Valeant stock price is soaring more than 5% to $28.49 today after a new report that the embattled Canadian drug giant received and rebuffed takeover overtures this spring.
The news does not change our bearish stance on Valeant.
By Jack Delaney, Sr. Cannabis Editor, Money Morning -
The Valeant Pharmaceuticals stock price has plummeted over the last 12 months, losing nearly 90% of its value.
Our Global Credit Strategist Michael Lewitt warned investors about this in October, and some of our readers have profited as much as 700%.
By Diane Alter, Contributing Writer, Money Morning -
The Valeant Pharmaceuticals stock price crashed another 20% this week amid newly released records that shed some light on the beleaguered drugmaker's operations.
The embattled drug giant also said it plans to release delayed Q1 2016 results in June, ahead of the July 31 deadline stipulated in the company's amended credit agreement.
Here's why we remain bearish...
By Diane Alter, Contributing Writer, Money Morning -
VRX stock has been on a huge rally recently.
After gaining nearly 27% last month, shares of Valeant stock are up another 7% so far this week.
But there's one reason we're still staying away from VRX stock in 2016...
By Diane Alter, Contributing Writer, Money Morning -
The VRX stock price rebounded 10% this week after announcing it has named drug-industry veteran Joseph Papa its next chairman and CEO as it attempts to restore investor confidence.
Papa comes with vast industry experience, but his appointment may be too little too late for Valeant.
Here's why we remain bearish on the VRX stock price...
By Diane Alter, Contributing Writer, Money Morning -
Down 67% year to date, Valeant stock has even further to fall.
In fact, Money Morning Global Credit Strategist Michael E. Lewitt says the Valeant stock price has no real value. He even calls for the firm's bankruptcy in the not-so-distant future.
Here's what you need to know...
By Michael E. Lewitt, Global Credit Strategist, Money Morning • @MichaelELewitt -
Valeant Pharmaceuticals has soared more than 26% in April. Last week, one analyst even called for VRX to double.
By Diane Alter, Contributing Writer, Money Morning -
The VRX stock price is falling again today following new default warnings for Valeant Pharmaceuticals.
Valeant shares are now down 70% year to date, and we still think they have even more room to fall.
Here's what you need to know about the VRX stock price today, and what's next for the company.